The Lancet: Russian Vaccine Trials Show Strong Immune Response

The Lancet: Russian Vaccine Trials Show Strong Immune Response

On Friday, the result of the vaccine trials of Sputnik-V was released, reported the Lancet. The result showed that the two formulations of a two-part vaccine have a good safety profile. There were no serious adverse events for more than 42 days and the antibody which was induced showed responses within 21 days.

The Lancet reported that the two-part vaccine includes two adenovirus vectors which are recombinant human adenovirus type 26 (rAd26-S) and recombinant human adenovirus type 5 (rAd5-S) – which have been modified to express the SARS-CoV-2 spike protein.

In July, results from the Oxford vaccine trial showed no early safety concerns, inducing strong immune responses in both parts of the immune system.

As per the journal, secondary outcomes from the trial denote that vaccines also produce a T cell response within 28 days.

There were findings from two small phase 1/2 trials reported the paper. These findings from two small phase 1/2 trials lasted 42 days. One of the findings was done on a frozen formulation of the vaccine and another involved a freeze-dried formulation of the vaccine.

the frozen formulation was for large-scale use while the freeze-dried formulation was for hard-to-reach regions. The freeze-dried formulation is more stable and they can be stored at 2-8 degrees Centigrade.

Lead author Denis Logunov of the N F Gamaleya National Research Centre for Epidemiology and Microbiology, Russia, explained why they used two adenoviruses. He says, “When adenovirus vaccines enter people’s cells, they deliver the SARS-CoV-2 spike protein genetic code, which causes cells to produce the spike protein”.

The trial of the vaccine took place in Russia within two hospitals. The trials included healthy adults aged 18-60 years. these adults self-isolated the moment they were registered for the trial and they remained in the hospital for the first 28 days of the trial.

The authors noted that more research is needed to evaluate the vaccine in different populations, including older age groups, individuals with underlying medical conditions, and people in at-risk groups.


Facebook Comments